American Journal of Clinical Pathology · 2012 · 76 citations · 12 references
MedicineMolecular BiologyOncologyBreast OncologyMolecular OncologyNeoplasiaCancer Molecular DiagnosticsHer2-positive Breast CancerMalignant NeoplasmsOncogene AmplificationBreast Cancer Molecular SubtypesBreast Pathology ReportingDna In Situ HybridizationHer2 Gene AmplificationPatterns
International and national guidelines highlight the importance of accuracy, reproducibility, and quality control of in situ hybridization (ISH) methods for testing breast carcinomas. However, few guidelines cover the reporting of ISH cases with "unusual" signal patterns, including, eg, heterogeneity and loss of chromosome enumeration probe or gene signals. These cases are, in fact, relatively frequent, and there is a need for developing evidence- or consensus-based reporting guidelines to ensure consistency of treatment. Following an audit of cases from a single center (including >1,700 cases) we show that approximately 10% of ISH results reflect unusual signal patterns. We illustrate the most common of these patterns and provide reporting guidelines for diagnosticians and recommendations for future research. Our goal is to ensure that in the future such "rogues" are reported in a consistent manner that, ultimately, will be supported by molecular and biochemical evidence.
12
Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz et al. · Journal of Clinical Oncology · 2006 · 4.5K citations · Full text
Caterina Marchiò, Maryou Lambros, Patrizia Gugliotta et al. · The Journal of Pathology · 2009 · 201 citations · Full text
Life Sciences, Genetics, Oncology +16